Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Coagulation factor IX conjugates

A technology of conjugates and factors, applied in the direction of drug combinations, blood diseases, biochemical equipment and methods, etc., can solve the problem of attachment of half-life extension parts that are not suitable for highly functionalized

Inactive Publication Date: 2016-10-12
NOVO NORDISK HEALTH CARE AG
View PDF23 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] However, the inventors have found that previously disclosed methods are not suitable for attaching highly functionalized half-life extending moieties such as carbohydrate polymers to GSCs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Coagulation factor IX conjugates
  • Coagulation factor IX conjugates
  • Coagulation factor IX conjugates

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0207] In one embodiment, the FIX polypeptide conjugated to HEP is wild-type FIX.

[0208] In one embodiment, the FIX polypeptide conjugated to HEP is wild-type FIX(a).

[0209] In another embodiment, the FIX polypeptide conjugated to HEP is an analog or variant having >95% sequence identity to wild-type FIX or FIX(a).

[0210] In one embodiment, the FIX of the HEP-FIX Polypeptide Conjugate is mutated such that it has enhanced proteolytic activity.

[0211] In one embodiment, the HEP polymer conjugated to the FIX polypeptide has a molecular weight of 5 to 15 kDa.

[0212] In one embodiment, the HEP polymer conjugated to the FIX polypeptide has a molecular weight of 15 to 25 kDa.

[0213] In one embodiment, the HEP polymer conjugated to the FIX polypeptide has a molecular weight of 25 to 35 kDa.

[0214] In one embodiment, the HEP polymer conjugated to the FIX polypeptide has a molecular weight of 35 to 45 kDa.

[0215] In one embodiment, the HEP polymer conjugated to the F...

Embodiment 1

[0354] Example 1: Quantitative method

[0355] The purity of the conjugates of the invention was analyzed by HPLC. HPLC was also used for conjugate quantification. Quantitation is based on the integration of the area under the curve using the absorption spectrum at a wavelength of 280 nm. Use manufactured by Wyeth Pharmaceuticals Inc. Recombinant coagulation factor IX was used as reference. A Zorbax 300SB-C3 column (4.6x50 mm; 3.5 μm Agilent, Cat. No.: 865973-909) was used. The column was operated on an Agilent 1100 Series HPLC equipped with a fluorescence detector (Ex 280nm, Em 348nm). The column temperature was 30 °C, the sample injection volume was 5 μg and the flow rate was 1.5 ml / min. The column was eluted with a water (A)-acetonitrile (B) solvent system containing 0.1% trifluoroacetic acid. The gradient program was as follows: 0 min (25% B); 4 min (25% B); 14 min (46% B); 35 min (52% B); 40 min (90% B); 40.1 min (25% B).

Embodiment 2

[0356] Embodiment 2: SDS-PAGE analysis

[0357] SDS PAGE analysis was performed using precast Nupage 7% tris-acetate gels, NuPage tris-acetate SDS running buffer and NuPage LDS sample buffer all from Invitrogen. Samples were denatured (70°C, 10 min) prior to analysis. HiMark HMW (Invitrogen) was used as standard. Electrophoresis was run at 150V, 120mA for 80min in an XCell Surelock Complete (Invitrogen) with power station. Gels were stained using SimplyBlue SafeStain from Invitrogen.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to Factor IX polypeptides conjugated to heparosan (HEP) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used - for example - in the treatment or prevention of bleeding disorders such as haemophilia B.

Description

technical field [0001] The present invention relates to conjugates between coagulation factor IX and heparosan polymers and uses thereof. Background technique [0002] In subjects with coagulation disorders, such as in persons with hemophilia, individual steps of the coagulation cascade become dysfunctional due to, for example, a deficiency or insufficient presence of coagulation factors. This dysfunction of part of the coagulation cascade results in inadequate blood clotting and potentially life-threatening bleeding or damage to internal organs such as joints. [0003] Hemophilia B is caused by a deficiency or dysfunction of coagulation factor IX activity, and its patients can be treated by on-demand administration of factor IX. [0004] Current treatment recommendations are shifting from traditional on-demand treatment to prevention. Current preventive therapies require multiple weekly doses, but for optimal plasma levels and efficacy, a daily injection would be preferab...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/48A61P7/02
CPCA61K38/4846A61K47/61A61P7/02A61P7/04C12N9/644C12N9/96C12Y304/21022
Inventor C.贝伦斯P.迪安格里斯F.M.哈尔勒
Owner NOVO NORDISK HEALTH CARE AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com